Tag Archive for: suspended

Medilink Therapeutics
Cancer

BioNTech: ADC study continues with conditions

Good news for BioNTech SE: The safety study of the ADC BNT326/YL202 developed by MediLink Therapeutics, which was suspended by the FDA in mid-June, will continue.

Read more